RE:Momentum KillerI've said it before, but this company needs to show something positive and not just a well done presentation. The judgement will cost more than we paid for Juvente. It's not crushing but its not insignificant either. Lots to look forward to in 2018 but in the meantime sales and revenue have been lagging. Hopefully Q4 will be enough to show that Ceapro is continuing in the right direction or at the minimum Q1 2018. I mentioned a couple days ago that I don't see it breaking out of this trading range until that happens. I believe it will be in the next 3-6 months through earnings releases and more info on functional drink.